Salutaris' brachytherapy device earns FDA market clearance
The Food and Drug Administration recently granted Salutaris Medical Devices market clearance for its SMD-Sr90-DA Radionuclide Brachytherapy Source device.
The SMD-Sr90-DA RBS device is intended for episcleral brachytherapy — the treatment of a specific type of eye cancer. Brachytherapy is an advanced cancer treatment which entails placing radioactive implants in or near a tumor itself to deliver high radiation doses.
According to Tucson, Ariz.-based Salutaris Medical Devices, the tool was developed for use within a manual brachytherapy applicator system.
More articles on supply chain:
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.